SCHEMBL3692887

SCHEMBL3692887

CCON=C(C(=O)O)c1ccccc1COc1ccc(C=C(Br)Br)cc1Cl

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MRGPRX4 Q96LA9 9/20 0.47
TP53 P04637 1/20 0.43
HTT P42858 1/20 0.43
SMN1; SMN2 Q16637 5/20 0.42
RAB9A P51151 4/20 0.42
NPC1 O15118 3/20 0.42
MAPT P10636 3/20 0.42
HIF1A Q16665 1/20 0.42
NFKB1 P19838 2/20 0.40
NFKB2 Q00653 2/20 0.40
RELA Q04206 2/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
POLB P06746 1/20 0.39
CTDSP1 Q9GZU7 1/20 0.39
S1PR4 O95977 1/20 0.38
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.38
HPGD P15428 1/20 0.38
S1PR1 P21453 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3688079 0.91 MRGPRX4 (0.48) MRGPRX4TP53HTTSMN1; SMN2RAB9A
SCHEMBL3686965 0.90 HIF1A (0.42) MRGPRX4TP53HTTSMN1; SMN2RAB9A
SCHEMBL3687896 0.90 HIF1A (0.46) MRGPRX4HTTSMN1; SMN2RAB9ANPC1
SCHEMBL3687121 0.90 HIF1A (0.42) MRGPRX4TP53HTTSMN1; SMN2MAPT
SCHEMBL3683351 0.90 HIF1A (0.54) HTTSMN1; SMN2RAB9ANPC1MAPT
SCHEMBL3752980 0.85 NR1H4 (0.45) SMN1; SMN2RAB9ANPC1MAPTHIF1A
SCHEMBL3759610 0.84 HIF1A (0.51) SMN1; SMN2RAB9ANPC1HIF1AMEN1
SCHEMBL3686104 0.84 HIF1A (0.41) MRGPRX4TP53HTTSMN1; SMN2RAB9A
SCHEMBL3688432 0.83 MAPT (0.46) MRGPRX4TP53HTTSMN1; SMN2RAB9A
SCHEMBL3692884 0.83 HIF1A (0.62) MRGPRX4TP53HTTSMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2231591-B1 METHOXYIMINO COMPOUNDS AND FUNGICIDE COMPOSITION COMPRISING SAME KYUNG NONG CORP (KR) 2015-02-11 EP claimed
US-8410302-B2 Methoxyimino compounds and fungicide composition comprising same KYUNG NONG CORPORATION (KR) 2013-04-02 US claimed
US-20100298593-A1 METHOXYIMINO COMPOUNDS AND FUNGICIDE COMPOSITION COMPRISING SAME KYUNG NONG CORPORATION (KR) 2010-11-25 US claimed
EP-2231591-A2 METHOXYIMINO COMPOUNDS AND FUNGICIDE COMPOSITION COMPRISING SAME Kyung Nong Corporation (KR) 2010-09-29 EP claimed
WO-2009072837-A2 METHOXYIMINO COMPOUNDS AND FUNGICIDE COMPOSITION COMPRISING SAME KYUNG NONG CORPORATION (KR) 2009-06-11 WO claimed
EP-2231591-B1 METHOXYIMINO COMPOUNDS AND FUNGICIDE COMPOSITION COMPRISING SAME KYUNG NONG CORP (KR) 2015-02-11 EP disclosed
US-8410302-B2 Methoxyimino compounds and fungicide composition comprising same KYUNG NONG CORPORATION (KR) 2013-04-02 US disclosed
US-20100298593-A1 METHOXYIMINO COMPOUNDS AND FUNGICIDE COMPOSITION COMPRISING SAME KYUNG NONG CORPORATION (KR) 2010-11-25 US disclosed
EP-2231591-A2 METHOXYIMINO COMPOUNDS AND FUNGICIDE COMPOSITION COMPRISING SAME Kyung Nong Corporation (KR) 2010-09-29 EP disclosed
WO-2009072837-A2 METHOXYIMINO COMPOUNDS AND FUNGICIDE COMPOSITION COMPRISING SAME KYUNG NONG CORPORATION (KR) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298593-A1 METHOXYIMINO COMPOUNDS AND FUNGICIDE COMPOSITION COMPRISING SAME CYP51A1, MSMO1, MTMR1 MRGPRX4 1060/4885TP53 3913/4885HTT 2051/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.